Log In
Print
BCIQ
Print
Print this Print this
 

GL-100, GLA-SE (ID-G100)

  Manage Alerts
Collapse Summary General Information
Company Immune Design Corp.
DescriptionToll-like receptor 4 (TLR4) agonist
Molecular Target Toll-like receptor 4 (TLR4)
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSkin cancer
Indication DetailsTreat Merkel cell carcinoma (MCC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today